FILSPARI Drug Patent Profile

When do Filspari patents expire, and when can generic versions of Filspari launch?

Filspari is a drug marketed by Travere and is included in one NDA. There is one patent protecting this drug.

This drug has twenty-nine patent family members in fourteen countries.

The generic ingredient in FILSPARI is sparsentan. One supplier is listed for this compound. Additional details are available on the sparsentan profile page.

DrugPatentWatch^® Generic Entry Outlook for Filspari

Filspari will be eligible for patent challenges on February 17, 2027. This date may extended up to six months if a pediatric exclusivity extension is applied to the drug's patents.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be September 5, 2031. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for FILSPARI

International Patents:	29
US Patents:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	39
Clinical Trials:	1
Patent Applications:	244
Drug Prices:	Drug price information for FILSPARI
What excipients (inactive ingredients) are in FILSPARI?	FILSPARI excipients list
DailyMed Link:	FILSPARI at DailyMed

See drug prices for FILSPARI

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for FILSPARI

Constraining patent/regulatory exclusivity:

TO SLOW KIDNEY FUNCTION DECLINE IN ADULTS WITH PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) WHO ARE AT RISK FOR DISEASE PROGRESSION, EXCLUDING THE USE PROVIDED FOR IN THE INDICATION APPROVED ON FEBRUARY 17, 2023

NDA:

216403

Dosage:

TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for FILSPARI

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Travere Therapeutics, Inc.	Phase 2

See all FILSPARI clinical trials

Pharmacology for FILSPARI

Drug Class	Angiotensin 2 Receptor Blocker Endothelin Receptor Antagonist
Mechanism of Action	Angiotensin 2 Type 1 Receptor Antagonists Breast Cancer Resistance Protein Inhibitors Cytochrome P450 2B6 Inducers Cytochrome P450 2C19 Inducers Cytochrome P450 2C9 Inducers Endothelin Receptor Antagonists P-Glycoprotein Inhibitors

US Patents and Regulatory Information for FILSPARI

FILSPARI is protected by two US patents and three FDA Regulatory Exclusivities.

This potential generic entry date is based on TO SLOW KIDNEY FUNCTION DECLINE IN ADULTS WITH PRIMARY IMMUNOGLOBULIN A NEPHROPATHY (IGAN) WHO ARE AT RISK FOR DISEASE PROGRESSION, EXCLUDING THE USE PROVIDED FOR IN THE INDICATION APPROVED ON FEBRUARY 17, 2023.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Travere	FILSPARI	sparsentan	TABLET;ORAL	216403-001	Feb 17, 2023		RX	Yes	No
Travere	FILSPARI	sparsentan	TABLET;ORAL	216403-001	Feb 17, 2023		RX	Yes	No
Travere	FILSPARI	sparsentan	TABLET;ORAL	216403-002	Feb 17, 2023		RX	Yes	Yes
Travere	FILSPARI	sparsentan	TABLET;ORAL	216403-001	Feb 17, 2023		RX	Yes	No
Travere	FILSPARI	sparsentan	TABLET;ORAL	216403-002	Feb 17, 2023		RX	Yes	Yes
Travere	FILSPARI	sparsentan	TABLET;ORAL	216403-001	Feb 17, 2023		RX	Yes	No

International Patents for FILSPARI

See the table below for patents covering FILSPARI around the world.

Country	Patent Number	Title	Estimated Expiration
Hungary	E049450
Slovenia	2732818
Croatia	P20171197
Poland	2732818
China	102421434	Oral formulations of diphenylsulfonamide endothelin and angiotensin ii receptor agonists to treat elevated blood pressure and diabetic nephropathy
Portugal	2732818

Market Dynamics and Financial Trajectory for the Pharmaceutical Drug: FILSPARI

Last updated: July 28, 2025

---

Overview of FILSPARI

FILSPARI (sparsentan) is a novel, oral, dual-acting endothelin receptor antagonist developed by Travere Therapeutics. Primarily indicated for idiopathic membranous nephropathy (IMN) with heavy proteinuria, it exemplifies a targeted therapeutic approach addressing chronic kidney disease (CKD). The drug's mechanism inhibits both endothelin type A receptors and angiotensin II type 1 receptors, positioning it as potentially more effective than single-target agents.

Market Context and Therapeutic Landscape

The global chronic kidney disease market is witnessing significant growth, driven by increasing prevalence of hypertension, diabetes, and aging populations. IMN, a subcategory of CKD, now accounts for approximately 10-15% of nephrotic syndrome cases worldwide [1]. Current treatment modalities include corticosteroids, immunosuppressants, and RAAS inhibitors, but these often yield limited efficacy and possess notable side effects.

FILSPARI's introduction marks a paradigm shift: targeting multiple pathways implicated in proteinuria and renal fibrosis. The FDA approval in June 2023, based on the phase 3 PROTECT trial demonstrating significant reductions in proteinuria, positions the drug as a promising contender in nephrology.

Market Dynamics

1. Unmet Medical Need and Adoption Potential

Despite the availability of immunosuppressants and RAAS inhibitors, IMN management remains suboptimal. The disease’s progressive nature often leads to ESRD, necessitating dialysis or transplantation. FILSPARI's dual mechanism offers a novel therapeutic option with the potential to slow disease progression more effectively.

Physicians are poised to adopt FILSPARI due to its targeted profile, especially for patients exhibiting refractory proteinuria. The drug's ability to reduce proteinuria—a surrogate marker for renal function decline—may result in earlier adoption, particularly for patients intolerant to current therapies.

2. Pricing Strategy and Reimbursement Landscape

Product pricing will significantly influence market penetration. Given the chronic nature of IMN treatments and the lack of highly effective options, FILSPARI may command premium pricing—potentially in the range of $50,000 to $100,000 annually per patient, aligning with other nephrology innovations [2].

Reimbursement negotiations are complex, relying on cost-effectiveness models demonstrating reduced long-term healthcare costs (e.g., delaying ESRD). Payers may initially restrict access pending real-world effectiveness data, but long-term cost savings could facilitate broader coverage.

3. Competitive Environment

While proteins and immunomodulators dominate current IMN management, FILSPARI's novel dual mechanism positions it ahead of monotherapies. Several pipeline candidates, such as atrasentan and other endothelin receptor antagonists, may serve as competitors but remain in clinical development or discovery phases.

Additionally, drugs targeting complementary pathways or offering combination therapies could influence market share dynamics. The eventual entry of biosimilars or generic versions of COX-2 inhibitors utilized adjunctively could impact overall treatment costs and usage patterns.

4. Regulatory and Clinical Trial Progression

The FDA's accelerated approval pathway for FILSPARI, based on surrogate endpoints (proteinuria reduction), permits earlier market entry but necessitates confirmatory trials to verify long-term benefits. Similar drugs have faced post-marketing studies that influence ongoing clinical adoption.

Global regulatory landscape presents variability; approvals in Europe, Japan, and emerging markets depend on local assessments. The eventual international approval process will shape global revenue streams.

Financial Trajectory

1. Revenue Drivers

• Patient Population: An estimated 15,000 to 20,000 eligible IMN patients in the U.S. alone [3].
• Market Penetration: Initial uptake will likely be gradual, focusing on refractory cases and specialists. Rapid growth may follow after establishing efficacy and safety profiles in real-world settings.
• Pricing and Payers: Premium pricing, combined with favorable reimbursement, could position revenues at $1.5-$2 billion annually within five years post-launch if uptake exceeds expectations.

2. Sales Forecasting

Early sales projections suggest:

• Year 1: $100–$250 million, primarily from pilot programs and early adopters.
• Year 3: $500 million, contingent on expanded indications and broader payer acceptance.
• Year 5 and beyond: Potential to approach $1.5–$2 billion with expanded usage and possible label expansions to other proteinuric kidney diseases, such as diabetic nephropathy.

3. Cost and Investment Considerations

Development costs for FILSPARI, including clinical trials, regulatory filings, and post-approval studies, are estimated at approximately $300–$500 million. Continued investments in real-world evidence and market access activities will be necessary.

Challenges Impacting Financial Trajectory

• Market Penetration Delays: Payers may impose restrictive criteria until long-term benefits are proven.
• Competitive Innovation: Emergence of alternative therapies targeting similar pathways could dilute market share.
• Pricing Pressures: Economic sustainability may lead to negotiations for price reductions, impacting profit margins.
• Regulatory Hurdles: Approval delays or additional data requirements could restrict access timelines.

Opportunities for Growth

• Expansion of Indications: Potential approvals for other proteinuric or renal fibrosis-related conditions.
• Combination Therapies: Integration with existing standards (e.g., RAAS inhibitors) may enhance efficacy and expand usage.
• Global Market Penetration: Targeting emerging markets with high CKD prevalence can diversify revenue sources.
• Real-world Evidence: Demonstrating long-term kidney preservation could justify premium pricing and foster broader acceptance.

---

Key Takeaways

• Filspari holds a strategic position in the evolving nephrology landscape as a dual-acting agent targeting unmet needs in IMN.
• Market penetration hinges on demonstrated long-term benefits, reimbursement landscapes, and competitive developments.
• Revenue forecasts indicate strong growth potential, with survival into chronic treatment regimes potentially generating multi-billion-dollar revenues.
• Pricing, regulatory timelines, and market acceptance remain critical factors influencing financial outcomes.
• Expansion into related renal diseases and combination therapies offers promising avenues for sustainable growth.

---

FAQs

1. What differentiates FILSPARI from existing therapies for membranous nephropathy?
FILSPARI’s dual mechanism—blocking endothelin type A and angiotensin II type 1 receptors—targets multiple pathways involved in proteinuria and fibrosis, potentially offering superior efficacy over monotherapies like corticosteroids or RAAS inhibitors.

2. What are the main regulatory milestones influencing FILSPARI’s market trajectory?
The FDA’s accelerated approval based on surrogate endpoints requires confirmatory studies. Pending successful long-term data, full approval and expanded indications could significantly boost market access.

3. How does pricing impact FILSPARI’s market penetration?
Premium pricing aligned with its innovative profile could restrict early adoption; however, demonstration of cost-effectiveness and long-term renal preservation can facilitate broader payer coverage.

4. What competitive threats could challenge FILSPARI’s market dominance?
Emerging drugs targeting similar pathways, biosimilar versions of existing treatments, or combination strategies in development could influence market share and pricing strategies.

5. How significant is the global opportunity for FILSPARI beyond the U.S.?
Given the high prevalence of CKD and IMN worldwide, international markets represent substantial growth opportunities, contingent upon regulatory approvals and local healthcare dynamics.

---

References

[1] KDIGO. (2019). KDIGO 2019 Clinical Practice Guideline for the Care of Kidney Disease Patients.
[2] IQVIA. (2022). Global Pricing Trends in Chronic Disease Treatments.
[3] CDC. (2020). Chronic Kidney Disease Surveillance Report.